抗抑郁药治疗背痛与骨关节炎的疗效与安全性:系统综述与荟萃分析
该系统综述与荟萃分析纳入33项随机对照试验共5318名受试者,评估抗抑郁药对比安慰剂治疗背痛和骨关节炎疼痛的疗效与安全性。中等确定性证据显示SNRIs对背痛的效果轻微且无临床重要性,但对骨关节炎的临床重要效果不能排除;TCAs和SNRIs对坐骨神经痛可能有效但证据确定性低至极低。
要点
- SNRIs对背痛疼痛和残疾的改善幅度小,无临床重要性(中等确定性)。
- SNRIs对骨关节炎疼痛可能具有临床重要效果,但不能排除(低确定性)。
- TCAs和SNRIs对坐骨神经痛可能有效,但证据确定性低至极低。
核心结论
- 中等确定性证据显示SNRIs对背痛疼痛和残疾评分的影响小且无临床重要性。
- 对骨关节炎,SNRIs的临床重要效果不能被排除。
- TCAs和SNRIs对坐骨神经痛可能有效,但证据确定性范围为低至极低。
研究设计与样本
- 系统综述与荟萃分析,检索Medline、Embase、Cochrane CENTRAL、CINAHL、International Pharmaceutical Abstracts、ClinicalTrials.gov和WHO ICTRP从建库至2020年5月12日。
- 纳入比较任何抗抑郁药与安慰剂(活性或惰性)的随机对照试验,受试者为下背痛或颈痛、坐骨神经痛或髋/膝骨关节炎患者。
- 共纳入33项试验,5318名受试者。
- 疼痛和残疾为主要结局,采用0(无痛/无残疾)至100(最痛/最重残疾)量表,使用随机效应模型计算加权均数差和95%置信区间。
- 使用Cochrane偏倚风险工具评估偏倚风险,采用GRADE框架评估证据确定性。
主要发现
- 中等确定性证据显示SNRIs在3-13周降低背痛(均数差-5.30,95%CI -7.31至-3.30)。
- 低确定性证据显示SNRIs在3-13周降低骨关节炎疼痛(均数差-9.72,95%CI -12.75至-6.69)。
- 极低确定性证据显示SNRIs在≤2周降低坐骨神经痛(均数差-18.60,95%CI -31.87至-5.33),但在3-13周未降低(均数差-17.50,95%CI -42.90至7.89)。
- 低至极低确定性证据显示TCAs在≤2周未降低坐骨神经痛(均数差-7.55,95%CI -18.25至3.15),但在3-13周降低(均数差-15.95,95%CI -31.52至-0.39),在3-12个月降低(均数差-27.0,95%CI -36.11至-17.89)。
- 中等确定性证据显示SNRIs在3-13周降低背痛相关残疾(均数差-3.55,95%CI -5.22至-1.88),在≤2周降低骨关节炎相关残疾(均数差-5.10,95%CI -7.31至-2.89),在3-13周为低确定性证据(均数差-6.07,95%CI -8.13至-4.02)。
关键数值与推荐
- SNRIs对背痛疼痛的均数差为-5.30(95%CI -7.31至-3.30),中等确定性。
- SNRIs对骨关节炎疼痛的均数差为-9.72(95%CI -12.75至-6.69),低确定性。
- SNRIs对背痛相关残疾的均数差为-3.55(95%CI -5.22至-1.88),中等确定性。
- TCAs对坐骨神经痛在3-12个月的均数差为-27.0(95%CI -36.11至-17.89),低至极低确定性。
- TCAs和其他抗抑郁药未降低背痛疼痛或残疾。
临床怎么用
- 对于背痛,SNRIs的疼痛和残疾改善幅度小且无临床重要性,不应作为主要治疗期望。
- 对于骨关节炎,SNRIs可能具有临床重要效果,但不能排除,可考虑个体化使用。
- 对于坐骨神经痛,TCAs和SNRIs可能有效,但证据确定性低至极低,需谨慎权衡。
局限性
- 不同结局的证据确定性从低至极低不等,尤其坐骨神经痛相关结论不确定性高。
- 原文未报告其他局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the efficacy and safety of antidepressants for back and osteoarthritis pain compared with placebo. DESIGN: Systematic review and meta-analysis. DATA SOURCES: Medline, Embase, Cochrane Central Register of Controlled Trials, CINAHL, International Pharmaceutical Abstracts, ClinicalTrials.gov, and the World Health Organization International Clinical Trials Registry Platform from inception to 15 November and updated on 12 May 2020. ELIGIBILITY CRITERIA FOR STUDY SELECTION: Randomised controlled trials comparing the efficacy or safety, or both of any antidepressant drug with placebo (active or inert) in participants with low back or neck pain, sciatica, or hip or knee osteoarthritis. DATA EXTRACTION AND SYNTHESIS: Two independent reviewers extracted data. Pain and disability were primary outcomes. Pain and disability scores were converted to a scale of 0 (no pain or disability) to 100 (worst pain or disability). A random effects model was used to calculate weighted mean differences and 95% confidence intervals. Safety (any adverse event, serious adverse events, and proportion of participants who withdrew from trials owing to adverse events) was a secondary outcome. Risk of bias was assessed with the Cochrane Collaboration's tool and certainty of evidence with the grading of recommendations assessment, development and evaluation (GRADE) framework. RESULTS: 33 trials (5318 participants) were included. Moderate certainty evidence showed that serotonin-noradrenaline reuptake inhibitors (SNRIs) reduced back pain (mean difference -5.30, 95% confidence interval -7.31 to -3.30) at 3-13 weeks and low certainty evidence that SNRIs reduced osteoarthritis pain (-9.72, -12.75 to -6.69) at 3-13 weeks. Very low certainty evidence showed that SNRIs reduced sciatica at two weeks or less (-18.60, -31.87 to -5.33) but not at 3-13 weeks (-17.50, -42.90 to 7.89). Low to very low certainty evidence showed that tricyclic antidepressants (TCAs) did not reduce sciatica at two weeks or less (-7.55, -18.25 to 3.15) but did at 3-13 weeks (-15.95, -31.52 to -0.39) and 3-12 months (-27.0, -36.11 to -17.89). Moderate certainty evidence showed that SNRIs reduced disability from back pain at 3-13 weeks (-3.55, -5.22 to -1.88) and disability due to osteoarthritis at two weeks or less (-5.10, -7.31 to -2.89), with low certainty evidence at 3-13 weeks (-6.07, -8.13 to -4.02). TCAs and other antidepressants did not reduce pain or disability from back pain. CONCLUSION: Moderate certainty evidence shows that the effect of SNRIs on pain and disability scores is small and not clinically important for back pain, but a clinically important effect cannot be excluded for osteoarthritis. TCAs and SNRIs might be effective for sciatica, but the certainty of evidence ranged from low to very low. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42020158521.
引用
- Ferreira GE, McLachlan AJ, Lin CC, et al. Efficacy and safety of antidepressants for the treatment of back pain and osteoarthritis: systematic review and meta-analysis. BMJ. 2021. PMID: 33472813. doi:10.1136/bmj.m4825
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。